Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Innovent Biologics's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 44.14.
Innovent Biologics's Days Inventory for the
six
months ended in Dec. 2025 was 239.87.
Innovent Biologics's Days Payable for the
six
months ended in Dec. 2025 was 91.5.
Therefore, Innovent Biologics's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 192.51.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Innovent Biologics Cash Conversion Cycle Related Terms
Innovent Biologics Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Innovent Biologics's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:6IB vs VRTX, REGN, ALNY: Cash Conversion Cycle Comparison
For the Biotechnology subindustry, Innovent Biologics's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Innovent Biologics Cash Conversion Cycle vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Innovent Biologics's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Innovent Biologics's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Innovent Biologics's Cash Conversion Cycle for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Innovent Biologics (STU:6IB) has a Cash Conversion Cycle of 192.51 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Innovent Biologics and its competitors.
Is Innovent Biologics' Cash Conversion Cycle too high?
Innovent Biologics' current Cash Conversion Cycle is 192.51. The Biotechnology industry median Cash Conversion Cycle is 103.45. Innovent Biologics' value of 192.51 is 86.1% above this industry median. Overall, Innovent Biologics has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Innovent Biologics' Cash Conversion Cycle compare to VRTX and REGN?
Innovent Biologics' Cash Conversion Cycle of 192.51 can be compared against companies in the Biotechnology industry. The industry median Cash Conversion Cycle is 103.45. Innovent Biologics' value of 192.51 is 86.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Biotechnology company?
The median Cash Conversion Cycle among Biotechnology companies is 103.45, based on 868 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Innovent Biologics's current Cash Conversion Cycle of 192.51 is 86.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Innovent Biologics and its competitors. For the Biotechnology industry, the median Cash Conversion Cycle is 103.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Innovent Biologics's current Cash Conversion Cycle is 192.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovent Biologics stock overvalued right now?
Based on GuruFocus' analysis, Innovent Biologics (STU:6IB) is currently considered Fairly Valued. The stock's GF Value™ is €11.08, compared to a current price of €10.10 — trading 8.8% below its estimated fair value. The current Cash Conversion Cycle is 192.51 and 86.1% above the Biotechnology industry median of 103.45. Innovent Biologics' overall GF Score™ is 80/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Innovent Biologics (STU:6IB), the current Cash Conversion Cycle is 192.51 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Innovent Biologics (STU:6IB) Overvalued in 2026?
Based on GuruFocus' analysis, Innovent Biologics stock appears to be undervalued.
The current stock price of €10.10 is trading 8.8% below its estimated GF Value™ of €11.08.
GuruFocus considers Innovent Biologics to be Fairly Valued.
Key valuation signals for STU:6IB:
Cash Conversion Cycle: 192.51
GF Value™: €11.08 vs. price of €10.10 (8.8% below fair value)
Industry Position: 86.1% above the Biotechnology median
No single metric tells the full story. See the STU:6IB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Innovent Biologics is one of the leading biotechnology companies in China. Listed on the Hong Kong stock exchange in 2018, Innovent has 12 commercialized oncology products and four commercialized nononcology products as of January 2026, and 34 drugs in its research and development pipeline. Its core assets are Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists (NRDL) for the first-line treatment of five major cancers, and mazdutide, a GLP-1/glucagon dual agonist drug for weight loss, fat breakdown, and Type 2 diabetes. Mazdutide is the first domestic GLP-1 drug produced and competes with Eli Lilly and Novo Nordisk in China. Tyvyt's main competition includes drugs from Junshi, Jiangsu Hengrui, BeOne, Merck, and Bristol Myers.
80GF Score
Get the complete analysis for STU:6IB
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6IB has been successfully added to your 
